← Back to Search

Kinase Inhibitor

XRD-0394 + Palliative Radiotherapy for Advanced Cancer

Phase 1
Waitlist Available
Research Sponsored by XRad Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests XRD-0394, a new oral drug that blocks proteins helping cancer cells repair, on patients with advanced or recurring cancer receiving radiation therapy. The goal is to see if it is safe and how well it works with radiation.

Eligible Conditions
  • Cancer
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: XRD-0394 80 mgExperimental Treatment2 Interventions
Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
Group II: XRD-0394 40 mgExperimental Treatment2 Interventions
Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
Group III: XRD-0394 160 mgExperimental Treatment2 Interventions
Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
Group IV: XRD-0394 (Dose TBD)Experimental Treatment2 Interventions
Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XRD-0394
2021
Completed Phase 1
~20
Palliative radiotherapy
2015
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

XRad Therapeutics IncLead Sponsor

Media Library

XRD-0394 (Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05002140 — Phase 1
Cancer Research Study Groups: XRD-0394 40 mg, XRD-0394 80 mg, XRD-0394 160 mg, XRD-0394 (Dose TBD)
Cancer Clinical Trial 2023: XRD-0394 Highlights & Side Effects. Trial Name: NCT05002140 — Phase 1
XRD-0394 (Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05002140 — Phase 1
~3 spots leftby Dec 2025